Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Tg Therapeutics Q3 2026 Results: Net Income $55.5M, Down 85.8% YoY

TG Therapeutics is focused on the commercialization of BRIUMVI for relapsing forms of multiple sclerosis and the development of its subcutaneous formulation and azer-cel. The company has a history of losses but is utilizing its commercial infrastructure to expand market acceptance while managing significant debt obligations and clinical trial expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue259.9161.7
Profit before tax73.925.9
Net income55.5390.9
EPS (diluted, $ a share)$0.35$2.43

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-85.8%
Revenue, year on year+60.7%
Operating margin33.0%
Source

10-Q filed with the SEC, NASDAQ: TGTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Tg Therapeutics, Inc.: key numbers

Share price
$62.76Close, Nov 16
Market cap
$9.49B
Shares outstanding
151.15MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Tg Therapeutics, Inc.

All →
7:05 AM ET 8-K
Financial Results

Tg Therapeutics Financial Results

TG Therapeutics reported Q3 2026 total global revenue of $259.9 million, driven by $232.6 million in U.S. net product revenue for BRIUMVI. The company raised its full-year 2026 total revenue guidance to approximately $1 billion and highlighted positive Phase 3 data for a simplified BRIUMVI initiation regimen.

Term
Q3 2026

“With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four years after launching BRIUMVI.”

Michael S. Weiss, Chairman and Chief Executive Officer

“Our increased full-year revenue guidance reflects the continued strength of our commercial business, while the approximately $100 million of shares repurchased during the quarter underscores our confidence in TG's long-term value.”

Michael S. Weiss, Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.